Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Core Insights - Cullinan Therapeutics, Inc. is participating in the Stifel 2025 Virtual Immunology and Inflammation Forum, highlighting its engagement in the biopharmaceutical sector [1] - The company focuses on developing targeted therapies for autoimmune diseases and cancer, aiming to create new standards of care [3] Company Overview - Cullinan Therapeutics is a biopharmaceutical company listed on Nasdaq under the ticker CGEM, dedicated to developing modality-agnostic targeted therapies [1][3] - The company has built a diversified portfolio of clinical-stage assets that target key disease drivers and utilize the immune system to combat diseased cells [3] - Cullinan's approach includes rigorous candidate selection and development processes to fast-track promising therapeutic molecules [3] Event Participation - Jeffrey Jones, M.D., M.B.A., the Chief Medical Officer of Cullinan, will participate in a fireside chat at the Stifel forum on September 16, 2025, at 9:30 a.m. ET [1] - A webcast of the event will be available on the company's investor relations website [2]